// App-Quantinova.ai

5559 : Agonist-redirected checkpoint (ARC), TIM3-Fc-OX40L, for cancer immunotherapy

Researchers

Presenter

  • George Fromm

Principal Investigators

  • Suresh de Silva

  • Kellsey Johannes

  • Arpita Patel

  • Josiah C. Hornblower

  • Taylor H. Schreiber

Medical Centers

  • Shattuck Labs, Inc., Durham, NC.

Locations

  • United States

Companies

  • Shattuck Labs, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Ecdysoneless

  • Tumor necrosis factor

Drug/Treatment

  • Abatacept

  • Etanercept

  • OX40L

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved